瘤性病毒疗法对儿科脑瘤的影响 - - 一项系统性审查
Praveen Nandha Kumar Pitchan Velammal1, Thirumalaivasan Dhasakeerthi2, Jonathan Roy Varghese3
1Department of Neurology, UTHSC, Memphis, TN, USA. praveennandhakumarpv@gmail.com.
概括
瘤性病毒疗法 (OVT) 对治疗儿科大脑瘤有希望,证明了安全性和可行性. 需要进一步的研究来确认它的生存益处,并优化对这些具有挑战性的儿童癌症的治疗策略.
科学领域:
- 在瘤学瘤学.
- 病毒学 病毒学
- 儿科医学 儿科医学
背景情况:
- 儿童死亡率对于儿科脑瘤 (PBT) 仍然很高.
- 目前的PBT治疗方法 (手术,化疗,放射治疗) 有其局限性.
- 瘤性病毒疗法 (OVT) 是一种新兴的癌症治疗策略,包括PBT.
研究的目的:
- 评估儿科脑瘤 (PBT) 瘤病毒治疗 (OVT) 的临床证据.
主要方法:
- 系统审查到2023年12月发表的临床试验.
- 搜索使用诸如"瘤病毒"",儿科脑瘤"和"临床试验"等术语的研究.
- 提取了有关患者特征,干预措施,生存结果和不良事件的数据.
主要成果:
- 四项试验包括40名患有恶性质瘤的儿科患者.
- 研究的抗瘤药物包括HSV G-207,DNX-2401,AdV-tk和Lerapolturev. 这两种病毒.
- 总体存活率在4.1至47.7个月之间;无进展存活率在1.7至47.7个月之间.
- 一般来说,OVT的耐受性很好,常见的副作用包括发烧和头痛;严重的不良事件很少发生.
- 许多患者在接受标准治疗的同时接受了OVT.
结论:
- 瘤性病毒疗法 (OVT) 对于儿科大脑瘤来说似乎是安全的和可行的.
- 在选择的儿科患者中有临床益处的迹象.
- 为了确定生存影响和最佳治疗策略,需要进行更大规模的受控试验.
相关概念视频
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Pharmacokinetics in Pediatric Patients: Drug Metabolism
191
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
191
Pharmacokinetics in Pediatric Patients: Drug Distribution
251
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
251
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
241
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
241
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Rous Sarcoma Virus (RSV) and Cancer
6.2K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
6.2K


